Developments Medtronic to buy SPR Therapeutics for ~$650 million Medtronic (NYSE: MDT) announced its intent to acquire SPR Therapeutics, a closely held medical technology company and a recognized leader in temporary, percutaneous peripheral nerve stimulation (PNS) therapies for... May 20, 2026